Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 8/20 | 0.61 |
| ▸ | ADH1B | P00325 | 2/20 | 0.61 |
| ▸ | ADH1C | P00326 | 2/20 | 0.61 |
| ▸ | ADH1A | P07327 | 2/20 | 0.61 |
| ▸ | ADH7 | P40394 | 2/20 | 0.61 |
| ▸ | ADH4 | P08319 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.39 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | CASP2 | P42575 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26441824 | 1.00 | EPHX1 (0.61) | EPHX1ADH1BADH1CADH1AADH7 | |
| SCHEMBL11104431 | 1.00 | EPHX1 (0.61) | EPHX1ADH1BADH1CADH1AADH7 | |
| SCHEMBL3250898 | 1.00 | EPHX1 (0.61) | EPHX1ADH1BADH1CADH1AADH7 | |
| SCHEMBL9206365 | 1.00 | EPHX1 (0.61) | EPHX1ADH1BADH1CADH1AADH7 | |
| SCHEMBL9629629 | 1.00 | EPHX1 (0.61) | EPHX1ADH1BADH1CADH1AADH7 | |
| SCHEMBL11099173 | 1.00 | EPHX1 (0.61) | EPHX1ADH1BADH1CADH1AADH7 | |
| SCHEMBL18116712 | 1.00 | EPHX1 (0.61) | EPHX1ADH1BADH1CADH1AADH7 | |
| SCHEMBL293426 | 1.00 | — | — | |
| SCHEMBL293423 | 0.97 | — | — | |
| SCHEMBL270590 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4235933-A2 | LITHIUM ION BATTERY USING CROSSLINKABLE SEPARATOR | Asahi Kasei Kabushiki Kaisha (JP) | 2023-08-30 | — | — | EP | disclosed |
| EP-4235940-A2 | LITHIUM ION BATTERY USING CROSSLINKABLE SEPARATOR | Asahi Kasei Kabushiki Kaisha (JP) | 2023-08-30 | — | — | EP | disclosed |
| EP-4220844-A2 | LITHIUM ION BATTERY USING CROSSLINKED SEPARATOR | Asahi Kasei Kabushiki Kaisha (JP) | 2023-08-02 | — | — | EP | disclosed |
| EP-4174075-A1 | 5-AMINOHEXAHYDRO-6,7,8-TRIHYDROXY-3H-OXAZOLO[3,4-A]PYRIDIN-3-ONE DERIVATIVES DERIVATIVES AS TLR4 MODULATORS FOR THE TREATMENT OF IMMUNE DISEASES | Consejo Superior de Investigaciones Científicas (CSIC) (ES) | 2023-05-03 | — | — | EP | disclosed |
| EP-4009437-A1 | COMPOSITE SINGLE-LAYER CHEMICALLY CROSS-LINKED SEPARATOR | Asahi Kasei Kabushiki Kaisha (JP) | 2022-06-08 | — | — | EP | disclosed |
| EP-3866219-A1 | LITHIUM ION BATTERY USING CROSSLINKED SEPARATOR | Asahi Kasei Kabushiki Kaisha (JP) | 2021-08-18 | — | — | EP | disclosed |
| EP-1207161-B1 | NOVEL ISOINDOLE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2006-01-18 | — | — | EP | disclosed |
| US-6777410-B2 | SUCH AS 9-(2-METHOXYPHENYL)-3-(1-METHYLETHYL)-(1,3)OXAZOLO-(2,3)ISOINDOLE-2,5(3H,9H)-DIONE; DIABETES AND COMPLICATIONS; OBESITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-08-17 | — | — | US | disclosed |
| US-20040053923-A1 | Novel isoindole derivatives | BANYU PHARMACEUTICAL CO., LTD. | 2004-03-18 | — | — | US | disclosed |
| US-6608098-B1 | Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-08-19 | — | — | US | disclosed |
| EP-1207161-A1 | NOVEL ISOINDOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053923-A1 | Novel isoindole derivatives | GPR119, SLC5A2, SLC5A1 | EPHX1 3176/4885ADH1B 372/4885ADH1C 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.